Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 13/20 | 0.38 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.33 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1358134 | 0.87 | ALDH1A1 (0.38) | CYP3A4 | |
| SCHEMBL1360417 | 0.82 | CYP3A4 (0.37) | CYP3A4 | |
| SCHEMBL1360376 | 0.74 | CYP3A4 (0.39) | CYP3A4 | |
| SCHEMBL1358136 | 0.73 | CYP3A4 (0.38) | CYP3A4 | |
| SCHEMBL1358327 | 0.73 | RAB9A (0.37) | CYP3A4HCRTR1HCRTR2 | |
| SCHEMBL1358324 | 0.73 | RAB9A (0.37) | CYP3A4HCRTR1HCRTR2 | |
| SCHEMBL1358325 | 0.73 | RAB9A (0.37) | CYP3A4HCRTR1HCRTR2 | |
| SCHEMBL1360029 | 0.72 | ALDH1A1 (0.36) | CYP3A4 | |
| SCHEMBL1358409 | 0.72 | ALDH1A1 (0.36) | CYP3A4 | |
| SCHEMBL1359241 | 0.72 | ALDH1A1 (0.36) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067442-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2011-11-29 | — | — | US | disclosed |
| US-20100081658-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081658-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, POLR2A, HCCS | CYP3A4 713/4885SLC22A12 4308/4885SLC22A6 3858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.